Loading
A phase 2 trial in colorectal cancer, run by Peking Union Medical College Hospital, now recruiting.
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT05601505 by Peking Union Medical College Hospital, with a registry enrolment figure of 470 participants, started 2023-02-03 and due to reach its primary completion in 2025-10-31. Interventions recorded: circulating tumor DNA. Conditions listed: Locally Advanced Rectal Carcinoma; Circulating Tumor DNA. Primary outcome: two-year disease-related treatment failure, 2y-DrTF. Colorectal eligibility wording from the registry: "Rectal adenocarcinoma confirmed by pathology;". Sites: China. No results are recorded here; the registry entry is the source.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.